PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34761497-6	2021	Further analysis of the underlying molecular mechanism underlying the MET suppression-induced drug sensitivity revealed that olaparib and crizotinib could together downregulate the ATM/ATR signaling pathway, inducing apoptosis by inhibiting the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway, enhancing the olaparib-induced antitumour effect in DU145 and PC3 cells.	olaparib	125-133	AKT serine/threonine kinase 1	Homo sapiens	294-297	
27055253-5	2016	Using reverse-phase protein array, we found the proteins most significantly upregulated following treatment with the PARP inhibitors olaparib and rucaparib were in the PI3K/mTOR pathway (p-mTOR, p-AKT, and pS6) (p<=0.02).	olaparib	133-141	AKT serine/threonine kinase 1	Homo sapiens	197-200	
26124328-3	2015	BEZ235 reduced olaparib-induced phosphorylation of p53 binding protein 1 (53BP1) and 53BP1 foci formation, as well as phosphorylation of AKT (S473).	olaparib	15-23	AKT serine/threonine kinase 1	Homo sapiens	137-140	
33669671-2	2021	In this study we examined the different responses of triple-negative breast cancer line MDA-MB-231 and hormone receptor-positive breast cancer line MCF7 to a combined treatment including olaparib, a poly-(ADP ribose) polymerase (PARP) inhibitor, oxaliplatin, a third-generation platinum compound and LY294002, an Akt pathway inhibitor.	olaparib	187-195	AKT serine/threonine kinase 1	Homo sapiens	313-316	
35419627-9	2022	Inhibition of AKT further increased the response of tumor cells to Olaparib in a PDX model derived from a recurrent platinum-resistant ovarian cancer patient.	olaparib	67-75	AKT serine/threonine kinase 1	Homo sapiens	14-17	
35419627-11	2022	Interestingly, mechanism study revealed that AKT inhibition decreased PARP enzyme activity as measured by PAR level and/or reduced PARP1 protein level in the tumor cell lines and PDX tumor tissues, which may explain the observed combined anti-tumor effect of LAE003 and Olaparib.	olaparib	270-278	AKT serine/threonine kinase 1	Homo sapiens	45-48	
32388810-7	2020	In addition, TRAF4"s effect on the sensitivity of EC cells to olaparib was further found to be mainly mediated by Akt phosphorylation.	olaparib	62-70	AKT serine/threonine kinase 1	Homo sapiens	114-117	
33093458-11	2020	Finally, our results suggested that olaparib inhibited the PI3K/AKT pathway in STAD cells, and up-regulation of ClC-3/SGK1 axis enhanced olaparib-induced PI3K/AKT pathway inhibition.	olaparib	137-145	AKT serine/threonine kinase 1	Homo sapiens	159-162	
27465688-9	2016	MK-2206 prevented cisplatin- and olaparib-induced AKT activation in the BRCA2-deficient PEO1 cells.	olaparib	33-41	AKT serine/threonine kinase 1	Homo sapiens	50-53	
31714594-11	2020	Treatment with olaparib increased phosphorylation of ATM and PTEN while decreasing the phosphorylation of AKT and mTOR and inducing autophagy.	olaparib	15-23	AKT serine/threonine kinase 1	Homo sapiens	106-109	
31438892-5	2019	Expression and phosphorylation of NF-kB, EGFR, Akt, p38, ERK was also observed in A549 and H1299 cells exposed with 12C ion with and without PARP-1 inhibition using siRNA or olaparib.	olaparib	174-182	AKT serine/threonine kinase 1	Homo sapiens	47-50	
30357520-8	2019	Downregulation of phospho-AKT levels and accumulation of gammaH2AX, a specific marker of DNA damage, were significantly and persistently induced by Olaparib and AZD2461 exposure, this leading to apoptosis-related cell death.	olaparib	148-156	AKT serine/threonine kinase 1	Homo sapiens	26-29	
27465688-11	2016	Higher AKT activity is also required to withstand cytotoxic agent-induced DNA damage, leading to strong synergism between MK-2206 and cisplatin or olaparib therapy in BRCA-deficient cells.	olaparib	147-155	AKT serine/threonine kinase 1	Homo sapiens	7-10